Skip to content

Study · Other design · n = 19 · 2018

5 results

Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers.

Labuschagne I, Poudel G, Kordsachia C, Wu Q, Thomson H, Georgiou-Karistianis N, Stout JC

Progress in neuro-psychopharmacology & biological psychiatry23 Sept 2017Cited by 24 (Europe PMC)

PMID28947180 (opens in a new tab)DOI10.1016/j.pnpbp.2017.09.023 (opens in a new tab)PepBankPUB-28947180
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanOther designMechanism

    In Huntington's disease gene carriers and controls, intranasal oxytocin produced significant group by drug interactions in brain activity to emotional faces in frontal and subcortical regions.

    In plain wordsIn people carrying the Huntington's disease gene and in controls, intranasal oxytocin changed brain responses to emotional faces differently in the two groups.

    Peptide
    Oxytocin
    Outcome
    MixedGroup by drug interaction in brain reactivity to emotional faces
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Permutation-based non-parametric statistical testing for the whole brain, showed significant group×drug interactions (p's<0.05, TFCE corrected) in areas of the left frontal pole, superior frontal, and middle frontal gyri cortically, and left putamen and thalamus sub-cortically.
    1 context sentence
    Summary · context
    In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intr…
  2. 02HumanOther designMechanism

    In Huntington's disease gene carriers, whose response to disgust stimuli was lower than controls under placebo, intranasal oxytocin raised the response to levels similar to controls.

    In plain wordsIn people carrying the Huntington's disease gene, intranasal oxytocin brought brain responses to disgusting images up to the level of controls.

    Peptide
    Oxytocin
    Outcome
    IncreaseBrain activity to disgust stimuli in HD carriers
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    After intranasal oxytocin, the pattern of activation to disgust stimuli was normalised in the HD group to similar levels as controls; eight of the nine HD carriers showed increased response in the middle frontal gyrus, and seven of the nine HD carriers showed increased response in the putamen.
    1 context sentence
    Summary · context
    In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intr…
  3. 03HumanOther designMechanism

    After intranasal oxytocin, eight of nine Huntington's disease gene carriers showed an increased response to disgust stimuli in the middle frontal gyrus.

    In plain wordsAfter intranasal oxytocin, most of the nine people carrying the Huntington's disease gene showed a stronger frontal brain response to disgusting images.

    Peptide
    Oxytocin
    Outcome
    IncreaseMiddle frontal gyrus response to disgust, individual HD carriers
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    eight of the nine HD carriers showed increased response in the middle frontal gyrus
    1 context sentence
    Summary · context
    In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intr…
  4. 04HumanOther designMechanism

    After intranasal oxytocin, seven of nine Huntington's disease gene carriers showed an increased response to disgust stimuli in the putamen.

    In plain wordsAfter intranasal oxytocin, most of the nine people carrying the Huntington's disease gene showed a stronger putamen brain response to disgusting images.

    Peptide
    Oxytocin
    Outcome
    IncreasePutamen response to disgust, individual HD carriers
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    seven of the nine HD carriers showed increased response in the putamen
    1 context sentence
    Summary · context
    In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intr…
  5. 05HumanOther designEfficacy outcome

    In Huntington's disease gene carriers and controls, intranasal oxytocin did not change subjective mood or state anxiety.

    In plain wordsIn people carrying the Huntington's disease gene and in controls, intranasal oxytocin did not change self-reported mood or anxiety.

    Peptide
    Oxytocin
    Outcome
    No significant changeSubjective mood and state anxiety
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    The observed effects of oxytocin occurred in the absence of changes in subjective mood or state anxiety.
    1 context sentence
    Summary · context
    In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intr…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.